Zanidatamab for HER2-Positive Advanced Tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests zanidatamab, a new drug designed to target HER2-positive cancers that have progressed despite prior treatment. It's for patients with advanced solid tumors of certain types (like endometrial, bladder, pancreatic, or colorectal cancer) whose tumors have a specific genetic marker called HER2 that makes them candidates for this therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Advanced cancer (spread or cannot be surgically removed) that has grown after at least one prior treatment
- Cancer must test positive for HER2 protein/gene amplification
- Able to provide a tumor tissue sample for HER2 confirmation testing
- Overall health stable enough for treatment (ECOG score 0–2)
- Heart function normal (ejection fraction ≥50%) and adequate blood/organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called zanidatamab in people with certain cancers (endometrial, colorectal, head & neck, non-small cell lung, or sarcoma) that have a specific change in the HER2 gene. It's for those whose cancer has spread or can't be removed and who have tried at least one prior treatment.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
This trial tests if the drug zanidatamab, given before surgery, can help treat colon or rectal cancer that has a specific marker called HER2. The goal is to see if this approach can shrink tumors and improve outcomes for people whose cancer has not spread to other parts of the body.
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
This trial tests a combination of two drugs, zanidatamab and tislelizumab, for people with HER2-positive gastrointestinal tumors, including stomach, gastroesophageal junction, and colorectal cancers. The goal is to see if this treatment can shrink or control the cancer.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.